28.05.2012 • News

Drugmaker Amylin Draws Initial Bids

Biotechnology company Amylin Pharmaceuticals has drawn initial bids from drugmakers Merck & Co and Sanofi, Bloomberg News reported on Friday, citing anonymous sources.

The drugmakers made offers of at least $25 a share, which would value Amylin at more than $4 billion, the report said.

Sources have told Reuters that Amylin, which sells the diabetes drugs Byetta and Bydureon, started reaching out to potential buyers in April.

Merck declined to comment. Amylin and Sanofi were not immediately available to comment.

 

 

 

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.